Day Two

Begin the final day of the conference by taking the opportunity to engage with people you missed on Day One and deepen initial discussions

• Exploring GLP-1 and muscle-expressing factor combinations that build muscle alongside fat loss to address GLP-1 induced sarcopenia
• Reviewing promising combination therapy and development innovations to maintain or improve lean mass during obesity treatments
• Determine the right development focus by evaluating whether muscle mass, muscle function, or overall muscle efficacy will be the most meaningful differentiator for future obesity therapies and clinical outcomes

• Stimulating the B2 adrenergic receptor to combat obesity
• Leveraging Atrogi’s GPCR discovery platform to discovery precise targets to manage metabolism
• Highlighting ATR-339 clinical data to demonstrate durable, muscle maintaining therapeutics

Enjoy morning refreshments, and plan your conversations for the final day of the event

• Exploring the role of serotonin signalling in regulating appetite, energy balance, insulin sensitivity, and glucose control through central and peripheral pathways
• Delving into the therapeutic potential of selective 5-HT2C receptor modulation to improve glycaemic outcomes and metabolic health beyond weight loss alone
• Unpacking obesity science, including underlying drivers, the neurology of feeding behaviours, genetic predisposition and disrupted metabolic regulation to reframe obesity treatments to target root causes
• Examining the redefinition of obesity based on excess adiposity plus adiposityderived comorbidities rather than BMI alone to develop therapies that align with evolving standards of success
• Exploring reliable and accurate measurements of success including metabolic and cardiovascular health markers, patient reported outcomes, comorbidity resolution and body composition measurements to truly demonstrate healthy weight loss

Enjoy lunch as you build upon the relationships from the summit so far

• Developing a drug that is purely selective for amylin receptors, does it matter?
• Exploring if they maintain pharmacologic effects
• Discussing the future for selective am

• Engineering xRNA to give weeks of GLP-1 pharmacology from one injection
• Optimising RNA chemistry to increase expression potency and durability beyond conventional mRNA
• Flattening peak-and-trough exposure to improve tolerability and adherence

Network with your key contacts from across the meeting and exchange details to build relationships beyond the event

• Optimising external ketones for therapeutic use to enhance energy expenditure
• Delivering high-quality weight loss with oral ketone therapy SNV-101 by reducing fat mass while combating comorbidity markers and preserving lean muscle
• Exploring the use of ketone therapeutics in combination with GLP-1 therapeutics to improve long-term durability and minimize post GLP-1 weight regain

• Decreasing BMI and pricing barriers to patient access of obesity and weight loss medication
• Exploring therapeutic and non-therapeutic methods to ensure weight maintenance beyond initial therapeutic application

• Leveraging the small intestine as synchronisation hub to trigger neuroendocrine neuronal signals that shape behaviour energy expenditure and metabolism
• Adapting behaviour and metabolism to secure long-term metabolic maintenance
• Exploring the intelligence system of L cells as key sensors and energetic and neural afferent effectors